ArticleFrontiers in cardiovascular medicine2020
Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.
Article in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Article
- Review
- Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity.Journal of infection and public health · 2021Review
- COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention.Expert review of anti-infective therapy · 2021Review
- ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2.Journal of virology · 2021Article
- The evolving cardiac lymphatic vasculature in development, repair and regeneration.Nature reviews. Cardiology · 2021Review
- Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Elderly Male With Cardiovascular-Related Comorbidities Has a Higher Rate of Fatal Outcomes: A Retrospective Study in 602 Patients With Coronavirus Disease 2019.Frontiers in cardiovascular medicine · 2021Article
- Recent Advances of COVID-19 Modeling Based on Regenerative Medicine.Frontiers in cell and developmental biology · 2021Review
- COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.Vascular health and risk management · 2021Review
- Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.International journal of antimicrobial agents · 2020Review
- Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients.The American journal of tropical medicine and hygiene · 2020Article
- Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications.Discoveries (Craiova, Romania) · 2020Review
- Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.Journal of clinical pharmacology · 2020Review
- Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.Frontiers in cardiovascular medicine · 2020Article
- Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19.Frontiers in cardiovascular medicine · 2020Article
- Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications.Frontiers in nutrition · 2020Article
- Mechanisms of Stroke in COVID-19.Cerebrovascular diseases (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2019, Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2, occurred in China and has currently led to a global pandemic. In addition to respiratory involvement, COVID-19 was also associated with significant multiple organ dysfunction syndrome (MODS). Cardiovascular impairment has been observed and is now drawing growing attention. Cardiovascular protective strategies are urgent and of great significance to the overall prognosis of COVID-19 patients. Direct viral infection, cytokine storm, and aggravation of existing cardiovascular diseases were recognized as possible mechanisms of cardiovascular impairment in COVID-19. Hyperactivated inflammation plays an important role in all three mechanisms and is considered to be fundamental in the development of cardiovascular impairment and MODS in COVID-19. Therefore, in addition to conventional cardiovascular treatment, anti-inflammatory therapy is a reasonable strategy for severe cases to further enhance cardiovascular protection and potentially mitigate MODS. We reviewed the inflammatory features and current promising treatments of COVID-19 as well as cardiovascular anti-inflammatory therapies that have been verified in previous clinical trials with positive outcomes. We believe that targeting the central pathway (IL-1β, TNF-α, IL-6), balancing the Th1 and Th2 response, and administering long-term anti-inflammatory therapy might be promising prospects to reduce cardiovascular impairment and even MODS during the acute and recovery phases of COVID-19. The cardiovascular anti-inflammatory therapies might be of great application value to the management of COVID-19 patients and we further propose an algorithm for the selection of anti-inflammatory therapy for COVID-19 patients with or at high risk of cardiovascular impairment. We recommend to take the experiences in cardiovascular anti-inflammatory therapy as references in the management of COVID-19 and conduct related clinical trials, while the clinical translation of novel treatments from preclinical studies or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.